CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
肿瘤细胞治疗研究
英文原题:Intraperitoneal transfer of microRNA-29b-containing small extracellular vesicles can suppress peritoneal metastases of gastric cancer.
Intraperitoneal transfer of microRNA-29b-containing small extracellular vesicles can suppress peritoneal metastases of gastric cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
小型细胞外囊泡(sEV)含有多种微RNA(miRNA),在肿瘤转移过程中发挥关键作用。腹膜转移(PM)患者腹膜外泌体中miR-29b水平明显降低,但其作用尚未完全阐明。
本研究探讨在小鼠模型中补充miR-29b能否影响PM形成。将人骨髓来源间充质干细胞(BMSC)UE6E7T-12转染整合miR-29b的重组慢病毒载体,并通过超速离心从培养上清中分离sEV。与阴性对照相比,这些sEV所含miR-29b显著增加。转化生长因子β1处理使人网膜组织来源间皮细胞(HPMC)的E-钙黏蛋白和钙网蛋白表达下降,同时波形蛋白和纤连蛋白表达增加;加入富含miR-29b的sEV后,上述效应完全消失。sEV分别使HPMC增殖和迁移降低15%(p<0.005,n=6)和70%(p<0.005,n=6),并使NUGC-4和MKN45细胞对HPMC的黏附分别降低90%(p<0.0001,n=5)和77%(p<0.0001,n=5)。采用小鼠BMSC同样制备富含miR-29b的sEV,并利用高转移性胃癌细胞克隆YTN16P建立同系小鼠模型,检测其体内效应。每3天腹腔注射sEV可显著减少YTN16P在肠系膜(p<0.05,n=6)和网膜(p<0.05,n=6)中的PM数量。骨髓间充质干细胞来源sEV可用作miR-29b腹腔递送的有效载体,以抑制胃癌PM形成。
Small extracellular vesicles (sEV) contain various microRNAs (miRNAs) and play crucial roles in the tumor metastatic process. Although miR-29b levels in peritoneal exosomes were markedly reduced in patients with peritoneal metastases (PM), their role has not been fully clarified. In this study, we asked whether the replacement of miR-29b can affect the development of PM in a murine model.
UE6E7T-12, human bone marrow-derived mesenchymal stem cells (BMSCs), were transfected with miR-29b-integrating recombinant lentiviral vector and sEV were isolated from culture supernatants using ultracentrifugation. The sEV contained markedly increased amounts of miR-29b compared with negative controls. Treatment with transforming growth factor- 1 decreased the expression of E-cadherin and calretinin with increased expression of vimentin and fibronectin on human omental tissue-derived mesothelial cells (HPMCs).
However, the effects were totally abrogated by adding miR-29b-rich sEV. The sEV inhibited proliferation and migration of HPMCs by 15% (p < 0. 005, n = 6) and 70% (p < 0. 005, n = 6), respectively, and inhibited adhesion of NUGC-4 and MKN45 to HPMCs by 90% (p < 0. 0001, n = 5) and 77% (p < 0. 0001, n = 5), respectively. MicroRNA-29b-rich murine sEV were similarly obtained using mouse BMSCs and examined for in vivo effects with a syngeneic murine model using YTN16P, a highly metastatic clone of gastric cancer cell.
Intraperitoneal (IP) transfer of the sEV every 3 days markedly reduced the number of PM from YTN16P in the mesentery (p < 0. 05, n = 6) and the omentum (p < 0. 05, n = 6). Bone marrow mesenchymal stem cell-derived sEV are a useful carrier for IP administration of miR-29b, which can suppress the development of PM of gastric cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。